Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher H van Dyck

Showing results (1-10 of 166) with videos related to

Pageof 17
Sort By:
Biological Psychiatry|October 3, 2017
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and PromiseChristopher H van Dyck
CNS Spectrums|July 9, 2004
Understanding the latest advances in pharmacologic interventions for Alzheimer's diseaseChristopher H van Dyck
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 21, 2026
Letter to the editor response for: "Schneider LS, Kennedy RE, Cutter G. Caution in interpreting disease-modification claims with lecanemab: selective reporting and causal inference. Alzheimer's & Dementia. 2026"Christopher H van Dyck
Biological Psychiatry|October 31, 2008
Imaging microglial activation in Alzheimer's disease: what does it mean?Christopher H van Dyck
The New England Journal of Medicine|January 4, 2023
Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for StrokeMarwan Sabbagh, Christopher H van Dyck
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 13, 2020
Alzheimer's & Dementia: The Journal of the Alzheimer's AssociationAdam P Mecca, Christopher H van Dyck
Neuropsychiatric Disease and Treatment|March 21, 2009
Memantine: efficacy and safety in mild-to-severe Alzheimer's diseaseRajesh R Tampi, Christopher H van Dyck
The New England Journal of Medicine|April 26, 2023
Lecanemab in Early Alzheimer's Disease. ReplyChristopher H van Dyck, Marwan Sabbagh, Sharon Cohen
Alzheimer'S & Dementia (New York, N. Y.)|May 15, 2023
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trialsChristopher H Van Dyck, Ryan S O'Dell, Adam P Mecca
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|May 4, 2006
A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezilChristopher H van Dyck, Frederick A Schmitt, Jason T Olin, et al.
Pageof 17

Showing results (1-10 of 166) with videos related to

Sort By:
Pageof 17
Biological Psychiatry|October 3, 2017
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and PromiseChristopher H van Dyck
CNS Spectrums|July 9, 2004
Understanding the latest advances in pharmacologic interventions for Alzheimer's diseaseChristopher H van Dyck
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 21, 2026
Letter to the editor response for: "Schneider LS, Kennedy RE, Cutter G. Caution in interpreting disease-modification claims with lecanemab: selective reporting and causal inference. Alzheimer's & Dementia. 2026"Christopher H van Dyck
Biological Psychiatry|October 31, 2008
Imaging microglial activation in Alzheimer's disease: what does it mean?Christopher H van Dyck
The New England Journal of Medicine|January 4, 2023
Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for StrokeMarwan Sabbagh, Christopher H van Dyck
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 13, 2020
Alzheimer's & Dementia: The Journal of the Alzheimer's AssociationAdam P Mecca, Christopher H van Dyck
Neuropsychiatric Disease and Treatment|March 21, 2009
Memantine: efficacy and safety in mild-to-severe Alzheimer's diseaseRajesh R Tampi, Christopher H van Dyck
The New England Journal of Medicine|April 26, 2023
Lecanemab in Early Alzheimer's Disease. ReplyChristopher H van Dyck, Marwan Sabbagh, Sharon Cohen
Alzheimer'S & Dementia (New York, N. Y.)|May 15, 2023
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trialsChristopher H Van Dyck, Ryan S O'Dell, Adam P Mecca
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|May 4, 2006
A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezilChristopher H van Dyck, Frederick A Schmitt, Jason T Olin, et al.
Pageof 17